📊 BIVIW Key Takeaways
Investment Thesis
BioVie is a pre-revenue pharmaceutical company with significant operational losses (-$11.5M operating income) and negative free cash flow (-$7.5M), indicating it is in active development phase with no commercial revenue generation. While the company maintains adequate liquidity with $20.5M cash against only $3.2M liabilities, current burn rate suggests runway of approximately 2.7 years at existing consumption levels. The absence of revenue combined with mounting losses and persistent negative returns on assets (-27.0%) and equity (-31.5%) indicates the company is capital-intensive with unproven commercial viability.
BIVIW Strengths
- Strong liquidity position with $20.5M cash and 7.25x current ratio providing near-term operational runway
- Minimal debt burden with only $62.5K long-term debt and 0.00x debt-to-equity ratio reducing financial distress risk
- Increased insider activity with 8 Form 4 filings in last 90 days suggesting management confidence or option exercises
BIVIW Risks
- Zero revenue with no commercial products generating sales, typical pre-clinical or early-stage biotech phase risk
- Negative operating cash flow of -$7.5M annually with current cash providing limited runway before requiring capital raise or achieving major milestones
- Persistent unprofitability with $11.5M operating losses and -31.5% ROE indicating inability to generate returns from equity capital invested
- Negative interest coverage of -1451.3x reflects operating losses exceeding any interest obligations and operational distress
Key Metrics to Watch
- Revenue generation from any approved product candidates or milestone achievement
- Monthly cash burn rate trend to assess sustainability of current runway
- Clinical trial progression and regulatory approvals for lead drug candidates
- Operating expense management and gross margin upon revenue initiation
- Capital raise requirements and dilution impact on existing shareholders
BIVIW Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 7.25x current ratio provides a solid financial cushion.
BIVIW Profitability Ratios
BIVIW vs Healthcare Sector
How BIOVIE INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BIVIW Balance Sheet & Liquidity
BIVIW 5-Year Financial Trend
5-Year Trend Summary: BIOVIE INC.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-73.05 indicates the company is currently unprofitable.
BIVIW Growth Metrics (YoY)
BIVIW Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2016 | N/A | -$54.6K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BIVIW Capital Allocation
BIVIW SEC Filings
Access official SEC EDGAR filings for BIOVIE INC. (CIK: 0001580149)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BIVIW
What is the AI rating for BIVIW?
BIOVIE INC. (BIVIW) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BIVIW's key strengths?
Strong liquidity position with $20.5M cash and 7.25x current ratio providing near-term operational runway. Minimal debt burden with only $62.5K long-term debt and 0.00x debt-to-equity ratio reducing financial distress risk.
What are the risks of investing in BIVIW?
Zero revenue with no commercial products generating sales, typical pre-clinical or early-stage biotech phase risk. Negative operating cash flow of -$7.5M annually with current cash providing limited runway before requiring capital raise or achieving major milestones.
What is BIVIW's revenue and growth?
BIOVIE INC. reported revenue of $0.0.
Does BIVIW pay dividends?
BIOVIE INC. does not currently pay dividends.
Where can I find BIVIW SEC filings?
Official SEC filings for BIOVIE INC. (CIK: 0001580149) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BIVIW's EPS?
BIOVIE INC. has a diluted EPS of $-1.70.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.